Method for monitoring secondary drug resistance of lung cancer patient to tyrosine kinase inhibitor through ddPCR technology

Abstract

The invention provides a method for monitoring secondary drug resistance of a lung cancer patient to a tyrosine kinase inhibitor through ddPCR technology, and an application of the method to monitoring and control of the tyrosine kinase inhibitor in a process of treating a lung cancer patient. The method comprises: firstly, extracting DNA from peripheral plasma of a lung cancer patient, then detecting a mutation condition of a drug-resistant mutation site T790M of EGFR in the DNA through adoption of ddPCR technology, and finally judging whether the patient produces drug resistance according to the mutation situation.

Description

technical field [0001] The invention relates to the fields of medicine and biotechnology, in particular to a molecular detection technology that can be used to guide tumor treatment, especially a method for highly sensitive detection of EGFR gene T790M site mutation in peripheral plasma / serum and its role in monitoring lung cancer patients' response to tyrosine Acid kinase inhibitors produce secondary drug resistance and other aspects of the application. Background technique [0002] With the development of biomedical technology, molecular targeted drugs have been widely used in the treatment of tumors. Compared with conventional chemotherapy, targeted therapy has the advantages of better effect and less side effects. Clinical application results show that some patients will develop drug resistance to targeted drugs. Research by the American Cancer Society shows that more than 90% of tumor patients are affected by drug resistance to varying degrees during treatment. The dr...

AI Technical Summary

Problems solved by technology

[0007] However, due to the extremely small amount of plasma cell-free DNA in the blood and the interference of a large amount of blood-derived DNA, it is still difficult to accurately isolate and purify DNA with high-efficiency DNA enrichment methods and high-sensitivity detection methods (such as sequencing, digital PCR). and reliably detect the specific types and sequences of tumor-associated cell-free DNA

For example, it has been reported in the literature that although the average content of circulating cell-free DNA (4771ng / ml) in patients with colorectal cancer is significantly different from that in healthy people (0.85ng / ml), for 67 patients with carcinoembryonic antigen (CEA) Only 47% of the test results are meaningful for diagnosis

[0008] Therefore, although the detection technology based on free blood DNA is the focus of research and development, there is still a lack of satisfactory mutant DNA detection technology in this field that can truly meet the clinical needs of high sensitivity, high accuracy and high reliability.

Images